```html

Rheumatic Iritis (Anterior Uveitis) – A Patient‑Friendly Guide

Overview

Rheumatic iritis, also called anterior uveitis, is inflammation of the iris and the anterior part of the uveal tract (the middle layer of the eye). When the inflammation is associated with systemic rheumatic diseases—such as ankylosing spondylitis, psoriatic arthritis, or Behçet’s disease—it is referred to as rheumatic iritis.

• Who it affects: Adults between 20‑40 years are most commonly diagnosed, with a slight male predominance in HLA‑B27 positive individuals. However, children with juvenile idiopathic arthritis (JIA) can also develop it.
• Prevalence: Anterior uveitis accounts for ~85 % of all uveitis cases. In the United States, the annual incidence is estimated at 24–50 cases per 100,000 people, and roughly 30 % of those are linked to an underlying rheumatic condition [1][2].
• Impact: If untreated, it can lead to vision loss, cataract, glaucoma, or permanent retinal damage.

Symptoms

Symptoms can appear suddenly (acute) or develop slowly (chronic). Common signs include:

• Eye redness – usually diffuse but more pronounced around the cornea (ciliary injection).
• Pain – a dull ache or sharp stabbing sensation, often worse in bright light (photophobia).
• Blurred vision – loss of sharpness, especially for near tasks.
• Floaters – tiny specks or threads drifting in the visual field.
• Photophobia – increased sensitivity to light.
• Tearing or watery discharge.
• Headache – especially around the brow or behind the eye.
• Reduced visual acuity – may be noticed when reading or driving.

In chronic disease, symptoms may be milder but persist for weeks to months, often alternating between eyes.

Causes and Risk Factors

Underlying Mechanisms

Rheumatic iritis results from an autoimmune response in which the body’s immune system mistakenly attacks ocular tissues. The exact cascade varies by disease:

• HLA‑B27 positivity – a genetic marker present in up to 90 % of patients with ankylosing spondylitis‑related iritis.
• Cytokine release – interleukin‑6 (IL‑6), tumor necrosis factor‑α (TNF‑α), and interferon‑γ drive inflammation of the iris.
• Molecular mimicry – bacterial or viral antigens may resemble eye proteins, triggering cross‑reaction.

Risk Factors

• Diagnosed rheumatic diseases (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, IBD‑associated arthritis, JIA, Behçet’s disease).
• Positive HLA‑B27 genotype.
• Family history of uveitis or autoimmune disease.
• Recent ocular trauma or surgery (though this is considered non‑rheumatic, it can coexist).
• Smoking – linked to higher activity of certain rheumatic diseases.
• Male sex (especially for HLA‑B27 associated forms).

Diagnosis

Prompt diagnosis is essential to prevent complications.

Clinical Examination

• Slit‑lamp biomicroscopy – the gold‑standard exam; reveals cells and flare in the anterior chamber, keratic precipitates on the corneal endothelium, and iris adhesions (posterior synechiae).
• Visual acuity test – measures baseline vision.
• Tonometry – checks intra‑ocular pressure (IOP); important because secondary glaucoma can develop.

Laboratory & Imaging Tests

• Blood tests for systemic disease:
  • HLA‑B27 typing.
  • ESR & CRP (markers of inflammation).
  • Autoantibodies (ANA, RF, anti‑CCP) if rheumatoid arthritis is suspected.
• Imaging of the affected joints (X‑ray, MRI) to confirm underlying rheumatic disease.
• In atypical cases, ultrasound biomicroscopy or anterior segment optical coherence tomography (AS‑OCT) can assess structural changes.

Treatment Options

Treatment aims to stop inflammation, relieve symptoms, and prevent long‑term damage.

Medications

1. Topical corticosteroids (e.g., prednisolone acetate 1 % drops):
   • First‑line for acute attacks.
   • Usually tapered over 4‑6 weeks based on clinical response.
2. Cycloplegic agents (e.g., cyclopentolate, atropine):
   • Relax the iris sphincter, prevent synechiae, and reduce pain.
3. Systemic corticosteroids (oral prednisone) – reserved for severe or bilateral disease, or when topical therapy fails.
4. Immunomodulatory therapy (IMT) for chronic or recurrent cases:
   • Methotrexate, mycophenolate mofetil, azathioprine.
   • Biologic agents targeting TNF‑α (e.g., adalimumab, infliximab) are especially effective in HLA‑B27 positive patients [3].
5. Non‑steroidal anti‑inflammatory drugs (NSAIDs) – adjunctive for pain, not sufficient alone.

Procedures

• Peripheral iridectomy – tiny surgical opening in the iris to relieve pressure when posterior synechiae threaten angle closure.
• Intravitreal steroid injection – reserved for refractory cases where rapid control is needed.
• Laser trabeculoplasty – may be considered if secondary glaucoma develops.

Lifestyle & Adjunct Measures

• Wear sunglasses to reduce photophobia.
• Avoid smoking and limit alcohol, which can exacerbate systemic inflammation.
• Maintain a balanced diet rich in omega‑3 fatty acids (found in fish, flaxseed) — evidence suggests modest anti‑inflammatory benefits.
• Adhere to a medication schedule; missing doses commonly leads to relapse.

Living with Rheumatic Iritis (Anterior Uveitis)

Daily Management Tips

• Medication diary – Write down each eye drop, time, and dose. Use alarms if needed.
• Follow‑up appointments – Initially weekly, then every 1‑3 months once stable.
• Protect your eyes – Use protective eyewear during sports or dusty environments.
• Monitor visual changes – Keep a simple log of reading clarity, glare, or new floaters.
• Joint health – Manage the underlying rheumatic disease with a rheumatologist; good systemic control reduces eye flare‑ups.
• Stress reduction – Chronic inflammation can be worsened by stress; practices like yoga, meditation, or gentle exercise can be helpful.

Prevention

While you cannot change genetic risk, several steps can lower the chance of an episode:

• Control the primary rheumatic disease with disease‑modifying agents and regular rheumatology visits.
• Stay up‑to‑date on vaccinations (influenza, pneumococcal) to reduce systemic infections that might trigger immune activation.
• Avoid eye trauma; wear safety glasses when needed.
• Quit smoking – improves both joint and ocular outcomes.
• Regular eye examinations even when asymptomatic, especially if you have known HLA‑B27 positivity.

Complications

If inflammation is not adequately suppressed, the following can occur:

• Glaucoma – increased intra‑ocular pressure damaging the optic nerve.
• Cataract formation – especially posterior subcapsular cataracts from long‑term steroid use.
• Band keratopathy – calcium deposits on the cornea causing visual distortion.
• Posterior synechiae – adhesions that can lead to angle‑closure glaucoma.
• Macular edema – swelling of the central retina, decreasing central vision.
• Permanent vision loss – rare but documented when chronic inflammation or complications are untreated.

According to the National Eye Institute, about 10 % of patients with recurrent anterior uveitis develop secondary glaucoma or cataract within 5 years [4].

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Uveitis.” Updated 2023. https://www.mayoclinic.org/...
2. Centers for Disease Control and Prevention. “Uveitis Surveillance.” 2022. https://www.cdc.gov/...
3. American College of Rheumatology. “Biologics for Ankylosing Spondylitis‑Associated Uveitis.” Arthritis Care Res. 2021;73(5):720‑728. DOI:10.1002/acr.2435
4. National Eye Institute. “Uveitis and Its Complications.” 2021. https://www.nei.nih.gov/...
5. World Health Organization. “Classification of Uveitis.” 2020. https://www.who.int/...

```